XML 76 R48.htm IDEA: XBRL DOCUMENT v3.25.4
License, Collaboration and Other Arrangements (Additional Information) (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Nov. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue   $ (411,328) $ (358,711) $ (310,463)
Research and development expense   30,604 13,654 33,922
Accounts receivable   34,966 20,392  
XACDURO        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue   (74,393) (21,070) (2,003)
Royalty Revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue   (236,479) (241,733) (238,846)
GIAPREZA        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue   (73,611) (55,037) (41,294)
License and other revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue   (2,719) (19,486) (11,000)
XERAVA        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue   (23,516) (21,385) (17,320)
Zai Lab        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue recognized     8,000  
Advance payments received     5,300  
Zai Lab | Amended Zai Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue recognized   1,300 8,100  
Accounts receivable   1,800 1,600  
Zai Lab | Interim Supply Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Accounts receivable   6,700 600  
Amount on net product sales recognized   37,900 6,300  
Zai Lab | Manufacturing Stage Transfer Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License and other revenue   1,100 3,400  
Zai Lab | XACDURO        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue recognized       3,000
Zai Lab | Research and Development Support | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Future potential milestone payment receivable   91,000    
Zai Lab | Royalty Revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues   2,400    
PAION AG | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Future potential milestone payment receivable   109,500    
PAION AG | Royalty Revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues   1,600 1,500 0
PAION AG | Cost Reimbursement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues   $ 2,700 0 1,300
Everest Medicines Limited        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Royalties payable period after first commercial sale of product   10 years    
Everest Medicines Limited | Commercial Supply Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues   $ 4,000 3,200 2,400
Percentage of reimbursed for direct and certain indirect manufacturing costs   110.00%    
Everest Medicines Limited | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales milestone payments receivable   $ 20,000    
Everest Medicines Limited | Royalty Revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues   3,600 4,700 1,400
Everest Medicines Limited | License and other revenue        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenues       8,000
GARDP Collaboration Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development expense   $ 1,000    
Basilea        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront payment under intangible asset     4,000  
George Washington University | GIAPREZA        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Percentage of royalty payable on net sales   6.00%    
Percentage of royalty on payments received from sublicensees   15.00%    
Royalty expense   $ 4,500 3,400 2,500
Harvard University        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Cost of license revenue       1,200
Percentage of royalty on payments received from sublicensees   20.00%    
Royalty expense   $ 1,400 1,400  
Harvard University | U.S.        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Percentage of royalty payable on net sales   5.00%    
Harvard University | Non-US        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Percentage of minimum royalty rate   4.50%    
Percentage of maximum royalty based on achievement of annual net product sales thresholds   7.50%    
Harvard University | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Clinical development and regulatory milestones amount payable   $ 15,100    
Paratek Pharmaceuticals, Inc | XERAVA        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Percentage of royalty payable on net sales   2.25%    
Claim expiration date   2023-10    
Massachusetts Institute of Technology        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront fee payment   $ 500    
Massachusetts Institute of Technology | Development Regulatory and Sales Milestone | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Future potential milestone payment receivable   17,500    
AstraZeneca | Durlobactam        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
One-time Milestone Payment on Net Sales   $ 5,000    
Term of the milestone payment on net sales   3 months    
Royalty expense   $ 0 $ 0 $ 0
AstraZeneca | Zoliflodacin        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
One-time milestone payment on commercial sales   $ 10,000    
Term of milestone payment for commercial sale   2 years    
Gates Foundation        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Grant Funding Maximum Amount $ 5,000      
License revenue recognized   $ 100    
Upfront fee received   $ 1,600